Skip to content
sellWeak10b5-1 plan

Bethany J Cavanagh sold $4,565 of BEAM

SVP, Finance and Treasurer at Beam Therapeutics Inc.. 187 shares at an average of $24.41, traded Oct 1, 2026, filed Oct 2, 2026.

Warning score
2
Value
$4,565
187 shares
Holdings after
50,984
-0% from before
From 52-week low
+18%
low $20.60, close $24.39
From 52-week high
-36%
high $37.92, as of Oct 1, 2026

Score components

  • Role
    CFO
    +22
  • Trade size
    $5k at market
    0
  • Share of holdings sold
    Sold 0.4% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

BEAMOct 9, 2026 · close 25.70
Since filing Oct 2, 2026: +4.9%SPY +1.2% · excess +3.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-412236, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 1, 2026SOpen-market sale
Common Stock10b5-1
-187$24.41$4,56550,98410 d ago

Related signals

Other insiders at Beam Therapeutics Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
15Weak
BEAMsell10b5-1
Beam Therapeutics Inc.
Giuseppe Ciaramella
President
$1.1M
35,000 shares
-16%
30Weak
BEAMsell 310b5-1
Beam Therapeutics Inc.
John M. Evans
CEO
$1.4M
50,000 shares
-5%
16Weak
BEAMsell 310b5-1
Beam Therapeutics Inc.
Christine Bellon
Chief Legal Officer
$47k
1,371 shares
-1%
34Weak
BEAMsell 310b5-1
Beam Therapeutics Inc.
Bethany J Cavanagh
SVP, Finance and Treasurer
$217k
6,198 shares
-15%
26Weak
BEAMsell 310b5-1
Beam Therapeutics Inc.
Bethany J Cavanagh
SVP, Finance and Treasurer
$91k
3,034 shares
-7%
35Weak
BEAMsell 310b5-1
Beam Therapeutics Inc.
Christine Bellon
Chief Legal Officer
$645k
18,629 shares
-16%
9Weak
BEAMsell 210b5-1
Beam Therapeutics Inc.
Christine Bellon
Chief Legal Officer
$34k
1,254 shares
-1%
21Weak
BEAMsell 210b5-1
Beam Therapeutics Inc.
Sravan Kumar Emany
Chief Financial Officer
$171k
6,294 shares
-8%
32Weak
BEAMsell
Beam Therapeutics Inc.
Fmr LLC
owner, other
$12k
459 shares
-97%
30Weak
BEAMsell 310b5-1
Beam Therapeutics Inc.
John M. Evans
CEO
$1.2M
50,000 shares
-5%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Bethany J Cavanagh sold $4,565 of BEAM | InsiderTell